Tag: file

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).

Company Announcement No 50/2026

CLAYMONT, Del., June 23, 2026 (GLOBE NEWSWIRE) -- Archimedes Tech SPAC Partners II Co. (Nasdaq: ATII), a publicly traded special purpose acquisition company (“ATII” or “Archimedes II”), today announced the filing with the U.S. Securities and Exchange Commission (the “SEC”), on June 22, 2026, of an amendment to the registration statement on Form S-4 (File No.: 333-295563) (as may be amended from time to time, the “Registration Statement”) previously filed in connection with the previously announced proposed business combination with Forge Nano, Inc. (“Forge Nano”). The Registration Statement includes a preliminary proxy statement/prospectus and has not yet been declared effective. The Registration Statement was filed by ATII Holdings Inc. (CIK 0002101833), ATII’s wholly-owned subsidiary (“Pubco”), and Forge Nano (CIK 0001719324) and is available free of charge at the SEC’s web site at www.sec.gov.

LOS ANGELES, June 23, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming July 27, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired AeroVironment, Inc. (“AeroVironment” or the “Company”) (NASDAQ: AVAV) securities between June 25, 2025 and March 10, 2026, inclusive (the “Class Period”).

TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced the next steps in connection with changes to the Company’s share capital (the “Share Capital Amendment”).